Brought to you by 
Biogen, Elan to co-develop and sell Antegren; deal terminated
22 Apr 2013
Executive Summary
Elan and Biogen have formed an exclusive worldwide agreement to develop, manufacture, and sell Elan's Antegren (natalizumab), a humanized monoclonal antibody now in Phase II clinical trials to treat multiple sclerosis and Crohn's disease, a chronic inflammatory gastrointestinal disorder.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biogen, Elan to co-develop and sell Antegren; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice